“…One case report demonstrated no clinical signs of melanoma or systemic disease at 3 years of follow-up in a patient with isolated TM. 8 Our patient in case 1 was also diagnosed with chronic lymphocytic leukemia, which is a recognized risk factor for melanoma, 9 though no studies have explored the relationship between chronic lymphocytic leukemia and TM. Provided that approximately one-third of melanomas arise from preexisting lesions, 10 we postulate that this case reflects a nevus-associated melanoma with subsequent complete regression.…”
“…One case report demonstrated no clinical signs of melanoma or systemic disease at 3 years of follow-up in a patient with isolated TM. 8 Our patient in case 1 was also diagnosed with chronic lymphocytic leukemia, which is a recognized risk factor for melanoma, 9 though no studies have explored the relationship between chronic lymphocytic leukemia and TM. Provided that approximately one-third of melanomas arise from preexisting lesions, 10 we postulate that this case reflects a nevus-associated melanoma with subsequent complete regression.…”
The mechanism underlying the efficacy of dupilumab in DEB is unknown, but blocking IL-4Ra-mediated sensitization of sensory neurons to various pruritogens has been proposed. 5 To the best of our knowledge, this is the first report of dupilumab in the treatment of pruritus in a DEB patient under 3 years old.This case supports that dupilumab may be considered an effective and safe treatment option for pruritus in these patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.